2126 WHAT IS A NORMAL NANOTECHNOLOGY PSA FOLLOWING RADICAL PROSTATECTOMY?

Lee C. Zhao,Dae Y. Kim,Daniel C. O'Brien,Donghui Kan,Norm D. Smith,Stacy Loeb,Chad A. Mirkin,C. Shad Thaxton,William J. Catalona

DOI: https://doi.org/10.1016/j.juro.2010.02.2214

2010-01-01

Abstract:You have accessJournal of UrologyProstate Cancer: Markers II1 Apr 20102126 WHAT IS A NORMAL NANOTECHNOLOGY PSA FOLLOWING RADICAL PROSTATECTOMY? Lee C. Zhao, Dae Y. Kim, Daniel C. O'Brien, Donghui Kan, Norm D. Smith, Stacy Loeb, Chad A. Mirkin, C. Shad Thaxton, and William J. Catalona Lee C. ZhaoLee C. Zhao Chicago, IL More articles by this author , Dae Y. KimDae Y. Kim Chicago, IL More articles by this author , Daniel C. O'BrienDaniel C. O'Brien Chicago, IL More articles by this author , Donghui KanDonghui Kan Chicago, IL More articles by this author , Norm D. SmithNorm D. Smith Chicago, IL More articles by this author , Stacy LoebStacy Loeb Baltimore, MD More articles by this author , Chad A. MirkinChad A. Mirkin Evanston, IL More articles by this author , C. Shad ThaxtonC. Shad Thaxton Chicago, IL More articles by this author , and William J. CatalonaWilliam J. Catalona Chicago, IL More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.2214AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Following radical retropubic prostatectomy (RRP), serum prostate specific antigen (PSA) values often are undetectable when measured using conventional PSA (cPSA) immunoassays with clinical limits-of-detection (LOD) of 0.1 ng/mL. Using a nanotechnology-enabled PSA research-use-only assay (nPSA, Nanosphere, Inc.) that is 2 orders of magnitude more sensitive than cPSA assays, the opportunity exists to define a nPSA level that is physiologic in men who have undergone RRP. By interrogating the serum of men who have undergone RRP and who have persistently undetectable cPSA levels, we hypothesize that the sensitivity advantage of the nPSA assay would provide an objective assessment of the PSA response to RRP and provide a new definition of “no evidence of disease” status. METHODS We analyzed banked serum samples from patients who had undergone RRP(n=273 patients, 480 serum samples). All patients had persistently undetectable cPSA levels and low, non-rising nPSA values. The median, mean, and range of nPSA values in the sub-100 pg/mL range were calculated for patients with short (0-5 years), medium (5-10 years), and long-term (>10 years) follow-up. RESULTS The median, mean, and range of nPSA values are shown in the Table and organized by duration of follow-up. Follow-Up Median Mean Std Dev Range High Range Low Patients Total Samples <5yrs 3.7 6.1 7.4 61.8 <0.5 115 266 5-10yrs 2.9 5.9 7.9 47.2 <0.5 83 134 >10yrs 3.9 7.7 10.5 57.5 <0.5 75 80 All 3.7 6.3 8.13 61.8 <0.5 273 480 CONCLUSIONS The nPSA assay provides an objective measure of PSA response to RRP, and suggests that a persistently non-rising nPSA level of approximately 5 pg/mL indicates a no-evidence of disease status. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e826 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Lee C. Zhao Chicago, IL More articles by this author Dae Y. Kim Chicago, IL More articles by this author Daniel C. O'Brien Chicago, IL More articles by this author Donghui Kan Chicago, IL More articles by this author Norm D. Smith Chicago, IL More articles by this author Stacy Loeb Baltimore, MD More articles by this author Chad A. Mirkin Evanston, IL More articles by this author C. Shad Thaxton Chicago, IL More articles by this author William J. Catalona Chicago, IL More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...